COMMUNIQUÉS West-GlobeNewswire

Ascendis Pharma Reports Third Quarter 2024 Financial Results
14/11/2024
– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA submission for achondroplasia planned for Q1 2025 followed by MAA [...]
NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
13/11/2024
Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing Gross profit margin for the quarter was 43.6% compared to 28.2% in Q3 of 2023 and 28.5% in [...]
UPDATE - Canada’s First Precision Health and Longevity Summit 2024: Uniting Global Leaders on November 15-16
13/11/2024
Unlocking the Future of Healthcare: Pioneering Strategies and Global Collaboration to Enhance Longevity and Health Outcomes for All Canadians CALGARY, Alberta, Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Precision Health and [...]
Calidi Biotherapeutics Announces Proposed Public Offering
13/11/2024
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies [...]
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
13/11/2024
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Jasper Therapeutics to Participate at Upcoming Investor Conferences
13/11/2024
REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
13/11/2024
- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - - Two new clinical trials, REFRαME-P1, a registration-enabling trial of luvelta for [...]
BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024
13/11/2024
MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2024 on [...]
Kriya Announces Publication of Preclinical Data for its Investigational AAV-FGF21 Gene Therapy Demonstrating Durable Reversal of Liver Fibrosis
13/11/2024
– Results demonstrate statistically significant fibrosis reversal and protection against hepatocellular carcinoma in animal models of MASH – – Kriya plans to evaluate KRIYA-497, a one-time intramuscular gene therapy [...]
Natural Alternatives International, Inc. Announces 2025 Q1 Results
13/11/2024
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today [...]
Telix ADSs Commence Trading on Nasdaq
13/11/2024
MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq [...]
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13/11/2024
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro potency data, [...]
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13/11/2024
– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 – – Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory AML [...]
Voting Rights and Shares Capital of the Company
13/11/2024
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 13, 2024 (GLOBE NEWSWIRE [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
13/11/2024
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 13 nov. 2024 (GLOBE NEWSWIRE) -- Paris, France, le 13 novembre 2024 Place de cotation [...]
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
13/11/2024
TORONTO and HAIFA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based [...]
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
13/11/2024
PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024 Launch of Iqirvo® (elafibranor) 1 on track with expectations; encouraging feedback from healthcare providers and [...]
GENFIT fait un point d’actualité sur ses activités à l’occasion de sa participation prochaine à l’AASLD Liver Meeting® 2024
13/11/2024
Programme PBC (sous licence Ipsen) : Ipsen présentera de nouvelles données sur elafibranor à l’AASLD Liver Meeting® 2024 Lancement commercial d’Iqirvo® (elafibranor) 1 conforme aux attentes ; retours encourageants des [...]
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
13/11/2024
Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses Intend to engage in clinical development [...]

Pages